Anzeige
Mehr »
Samstag, 26.07.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1CXBG | ISIN: FR0010557264 | Ticker-Symbol: A8D
Tradegate
25.07.25 | 18:06
1,396 Euro
+0,14 % +0,002
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
AB SCIENCE SA Chart 1 Jahr
5-Tage-Chart
AB SCIENCE SA 5-Tage-Chart
RealtimeGeldBriefZeit
1,3801,41210:02
1,3841,40225.07.

Aktuelle News zur AB SCIENCE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoAB Science erhält Zulassung für konfirmatorische ALS-Studie in Europe6
DoAB Science gets approval to start ALS drug confirmatory trial in Europe1
DoAB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS107PRESS RELEASE AB SCIENCE HAS RECEIVED APPROVAL FROM SEVERAL EUROPEAN COUNTRIES TO INITIATE THE CONFIRMATORY PHASE 3 STUDY OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS THIS APPROVAL FOLLOWS PROTOCOL...
► Artikel lesen
08.07.AB Science announces the successful completion of a EUR 1.925 million private placement8
04.07.FDA And EMA Approve AB Science's Phase 3 Masitinib Trial In MCRPC406PARIS (dpa-AFX) - AB Science (ABSCF.PK) announced FDA and EMA authorization of a confirmatory Phase 3 trial of masitinib in metastatic castrate-resistant prostate cancer, using a harmonized...
► Artikel lesen
04.07.AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer113PRESS RELEASE MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3 TRIAL IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER, WITH BIOMARKER-DRIVEN PATIENT SELECTION TARGETING POPULATION...
► Artikel lesen
AB SCIENCE Aktie jetzt für 0€ handeln
30.06.AB Science Reaches Agreement In Principle With Financial Creditors301BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - AB Science (ABSCF.PK) said an agreement in principle has been reached with its financial creditors to postpone by 24 months the repayment of its bank debt....
► Artikel lesen
30.06.AB Science provides an update on the renegotiation of loan repayment terms with its financial creditors2
23.06.AB Science: New Peer-Reviewed Masitinib Trial Shows Strong Evidence Supporting Potential To Treat AD341PARIS (dpa-AFX) - French pharmaceutical company AB Science SA (ABSCF.PK) announced Monday that a new peer-reviewed data provide strong evidence supporting Masitinib's potential for the treatment...
► Artikel lesen
23.06.AB Science - New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer's disease144PRESS RELEASE NEW PEER-REVIEWED DATA PROVIDE STRONG EVIDENCE SUPPORTING MASITINIB'S POTENTIAL FOR THE TREATMENT OF ALZHEIMER'S DISEASE THROUGH A DUAL MECHANISM OF COGNITIVE ENHANCEMENT AND NEUROPROTECTION...
► Artikel lesen
09.06.AB Science: EMA Approves Shelf-Life Extension For MASIVET To 48 Months383PARIS (dpa-AFX) - AB Science (ABSCF.PK) announced that the European Medicines Agency (EMA) has approved an extension of the shelf life of its veterinary medicine, MASIVET, to 48 months from...
► Artikel lesen
09.06.AB Science announces EMA approval of Masivet shelf-life extension to 4 years173PRESS RELEASE AB SCIENCE ANNOUNCES EMA APPROVAL OF MASIVET® SHELF-LIFE EXTENSION TO 4 YEARS Paris, June 9, 2025, 8am CET AB Science SA (Euronext - FR0010557264 - AB) today announced that the European...
► Artikel lesen
23.05.AB Science announces the settlement delivery of its latest capital increase for €1.8 million145PRESS RELEASE AB SCIENCE ANNOUNCES THE SETTLEMENT DELIVERY OF ITS LATEST CAPITAL INCREASE FOR €1.8 MILLION Paris, May 23, 2025, 8am CET AB Science S.A. (the "Company" or "AB Science", Euronext...
► Artikel lesen
20.05.AB Science announces the successful completion of a EUR 1.8 million private placement5
19.05.AB Science Receives Chinese Patent Protecting Masitinib To Treat Covid-19 Until 2041; Stock Up320BEIJING (dpa-AFX) - French pharmaceutical company AB Science SA (ABSCF.PK) announced Monday that it has received Chinese patent protecting Masitinib in the treatment of Covid-19 until April...
► Artikel lesen
19.05.AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection144PRESS RELEASE AB SCIENCE RECEIVES CHINESE PATENT PROTECTING MASITINIB IN THE TREATMENT OF COVID-19 UNTIL 2041, ADDING ONE MORE INDICATION WITH LONG TERM INTELLECTUAL PROPERTY PROTECTION Paris, May...
► Artikel lesen
15.05.AB Science today reports a new publication in the scientific journal PLOS One, showing promising neuroprotective effects of masitinib2
12.05.AB Science Posts Narrower Loss In FY24269BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - AB Science SA (ABSCF.PK) posted a fiscal 2024 net loss of 7.8 millon euros compared to a loss of 12.0 million euros, prior year. Basic loss per share was...
► Artikel lesen
12.05.AB Science reports its revenues for the year 2024 and provides an update on its activities881PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION AS OF DECEMBER 31, 2024 AND THE KEY EVENTS OF THE PERIOD Financial and corporate situation Operating deficit of 6,1 million euros...
► Artikel lesen
05.05.AB Science will present new data from masitinib clinical program in ALS in two presentations at the 2025 ENCALS Annual Meeting1
Weiter >>
30 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1